November 10, 2025 — Leads & Copy — QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company focused on transforming breast health management with radiation-free imaging technology, has appointed Satrajit Misra as its Chief Commercial Officer (CCO).
The appointment highlights QT Imaging’s commitment to innovation, clinical excellence, and commercial execution in delivering accessible, radiation-free, contrast-free, and compression-free breast imaging technologies for women globally.
According to Dr. Raluca Dinu, CEO of QTI, the company is thrilled to welcome Satrajit as CCO as they advance commercialization and pivot toward a SaaS and biomarker-driven franchise. Dinu stated that Misra’s experience in building and scaling medical imaging franchises, his relationships with radiology and oncology thought leaders, and his success in driving growth and innovation across imaging and MedTech enterprises will be instrumental in accelerating the adoption of their diagnostic technologies.
Mr. Misra is recognized for his experience in scaling businesses, leading acquisitions and integrations, and forging alliances to expand into white-space markets. Before joining QT Imaging, Misra was Executive Senior Vice President, Chief Sales and Marketing Officer at Canon Medical Systems USA (“Canon USA”), a strategic partner of QT Imaging. Prior to Canon USA, Misra held leadership positions at Philips and Siemens Healthcare.
In his new role as CCO, Misra will drive commercial scale-up and clinical partnerships, positioning QT Imaging as a modality of choice for supplemental breast screening and biomarker-driven precision diagnostics.
Mr. Misra stated he is excited to join QTI as they bring their transformative breast imaging technology to scale and redefine standards in early detection and precision diagnostics. He added that he looks forward to working with the QTI team to develop and expand the product pipeline, accelerate growth, and enhance value for their shareholders.
QT Imaging Holdings, Inc. strives to improve global health outcomes, focusing on safe, affordable, accessible, and patient-centered medical imaging for the detection, diagnosis, and treatment of disease.
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves.
Forward-Looking Statements:
This press release contains forward-looking statements. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including its transformation from a hardware-focused startup to a biomarker-driven AI imaging company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement.
Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110081345/en/
Source: QT Imaging Holdings, Inc.
